Core Insights - Actuate Therapeutics, Inc. has completed patient enrollment in a Phase 2 trial for elraglusib in combination with FOLFIRINOX and losartan for untreated metastatic pancreatic adenocarcinoma (mPDAC) [1][2][3] - The trial enrolled 56 treatment-naïve mPDAC patients, focusing on safety, tolerability, and progression-free survival [2] - Initial data from the trial indicates enhanced clinical activity of elraglusib when combined with FOLFIRINOX and losartan [3][7] - The final results from the trial are anticipated in 2026 [3][7] Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on therapies for high-impact, difficult-to-treat cancers [4] - The lead investigational drug, elraglusib, is a novel GSK-3β inhibitor targeting pathways that promote tumor growth and resistance to conventional therapies [4] - Elraglusib is designed to enhance anti-tumor immunity by inhibiting NF-kB and regulating immune checkpoints [4] Research Collaboration - The trial is led by Dr. Colin Weekes at Massachusetts General Hospital, with support from the Lustgarten Foundation and participation from other institutions [1][3] - Massachusetts General Hospital is noted for conducting the largest hospital-based research program in the U.S., with over $1 billion in annual research operations [5]
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer